SYSTEMIC SCLEROSIS CLINICAL STUDY PATIENT INFORMATION

STUDY INFORMATION

Corbus Pharmaceuticals is looking for patients to participate in a research study of lenabasum (JBT-101) for diffuse cutaneous systemic sclerosis (scleroderma). This is a Phase 3 study and is the second study Corbus is conducting involving people living with scleroderma.

WHAT IS LENABASUM?

Lenabasum (JBT-101) is an experimental drug that may reduce inflammation and stop the development of scar tissue, also called fibrosis, that results from chronic active inflammation. While there are no known treatments that can repair the damage already done, lenabasum may reduce or resolve disease symptoms and prevent further damage to tissue and organs in patients with chronic over-active inflammatory and fibrotic diseases such as scleroderma.



ARE YOU ELIGIBLE TO PARTICIPATE?

To participate, you must meet the following requirements*:

- Have a diagnosis of diffuse cutaneous systemic sclerosis.
- Must be 18 or older to enroll in the study.
- A disease duration of **6 years or less** from the first non-Raynaud's symptom; If disease duration is **more than 3 years and less than or equal to 6 years,** then mRSS (Modified Rodnan Skin Score) must be **15 or greater**.

DURATION OF STUDY:

The expected duration of this study is 12 months of study treatment. During these 12 months you will be placed into one of three study treatment groups, with 5mg, 20mg and placebo doses being tested.

Those that complete the study may have the opportunity to participate in an extension of this study where you would be given the active investigational product.

ADDITIONAL INFORMATION:

- If stable on your current medications, usually you will **NOT** need to stop them or change the dose.
- Immunomodulating medications are allowed.*
- Participation in this study is voluntary and if you choose to participate, you may withdraw at any time, for any reason.

**There are additional criteria you must meet to be able to participate in this study.*

If you are interested in participating in this study, please contact us at:

Corbus Pharmaceuticals
100 River Ridge Drive, Suite 103 • Norwood, MA 02062
617.963.0707 • www.corbuspharma.com
sscpatients@corbuspharma.com
sscphysicians@corbuspharma.com

CORBUS PHARMACEUTICALS
Developing Breakthrough Therapies for Rare Inflammatory Diseases